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Summary
Background Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two 
decades, the outcome of those who relapse has remained static. We investigated the outcome of children with acute 
lymphoblastic leukaemia who relapsed on present therapeutic regimens.
Methods This open-label randomised trial was undertaken in 22 centres in the UK and Ireland and nine in Australia 
and New Zealand. Patients aged 1–18 years with ﬁ rst relapse of acute lymphoblastic leukaemia were stratiﬁ ed into 
high-risk, intermediate-risk, and standard-risk groups on the basis of duration of ﬁ rst complete remission, site of 
relapse, and immunophenotype. All patients were allocated to receive either idarubicin or mitoxantrone in induction 
by stratiﬁ ed concealed randomisation. Neither patients nor those giving interventions were masked. After three 
blocks of therapy, all high-risk group patients and those from the intermediate group with postinduction high minimal 
residual disease (≥10–⁴ cells) received an allogenic stem-cell transplant. Standard-risk and intermediate-risk patients 
with postinduction low minimal residual disease (<10–⁴ cells) continued chemotherapy. The primary outcome was 
progression-free survival and the method of analysis was intention-to-treat. Randomisation was stopped in 
December, 2007 because of diﬀ erences in progression-free and overall survival between the two groups. This trial is 
registered, reference number ISCRTN45724312.
Findings Of 239 registered patients, 216 were randomly assigned to either idarubicin (109 analysed) or mitoxantrone 
(103 analysed). Estimated 3-year progression-free survival was 35·9% (95% CI 25·9–45·9) in the idarubicin group 
versus 64·6% (54·2–73·2) in the mitoxantrone group (p=0·0004), and 3-year overall survival was 45·2% (34·5–55·3) 
versus 69·0% (58·5–77·3; p=0·004). Diﬀ erences in progression-free survival between groups were mainly related to 
a decrease in disease events (progression, second relapse, disease-related deaths; HR 0·56, 0·34–0·92, p=0·007) 
rather than an increase in adverse treatment eﬀ ects (treatment death, second malignancy; HR 0·52, 0·24–1·11, 
p=0·11).
Interpretation As compared with idarubicin, mitoxantrone conferred a signiﬁ cant beneﬁ t in progression-free and 
overall survival in children with relapsed acute lymphobastic leukaemia, a potentially useful clinical ﬁ nding that 
warrants further investigation.
Funding Cancer Research UK, Leukaemia and Lymphoma Research, Cancer Council NSW, and Sporting Chance 
Cancer Foundation.
Introduction
In the past three decades, survival in children with acute 
lymphoblastic leukaemia has improved from 50% to 
more than 80%.1 For patients who relapse, changes in 
subsequent management have had little eﬀ ect on 
outcome,2 and acute lymphoblastic leukaemia remains a 
leading cause of death in childhood. The overall survival 
of relapsed acute lymphoblastic leukaemia has remained 
between 46% and 56% in the UK from 1991 to 2003.3,4 
Similar outcomes have been reported by the Berlin 
Frankfurt Münster group in Germany5 and Children’s 
Oncology Group in the USA.6 During this time, the 
pattern of relapse has changed, with a proportionate 
increase in patients who have disease recurrence within 
the CNS.7 To meet these challenges, a total redesign of 
the management of relapsed acute lymphoblastic 
leukaemia was undertaken in the UK, and the ALLR3 trial 
opened in 2003.
Intergroup study results have shown that the outcome 
after a relapse improves with the length of ﬁ rst 
remission.4–6 Some late relapses are thought to arise from 
a common precursor that retains the chemosensitivity of 
the original clone, which could explain the high cure rates 
achieved with chemotherapy alone in late relapses. In the 
UK most relapses occur late,7 and ALLR3 was thus 
designed to have a conventional four-drug induction with 
continuous asparagine depletion throughout the ﬁ rst 
3 months. This approach eﬀ ectively achieves remission 
in patients with relapsed disease.4–6,8 For more resistant 
disease, a second block of non-cross resistant drugs (at 
the time of protocol design, cyclophosphamide and 
etoposide) was introduced. To target the extramedullary 
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compartment, intrathecal methotrexate and high-
dose CNS penetrating schedules of cytarabine9 and 
methotrexate10 in a Capizzi11 design were introduced. A 
randomisation of idarubicin or mitoxantrone was intro-
duced in induction. The choice of idarubicin was based 
on its previous use in relapsed acute lymphoblastic 
leukaemia11,12 and on the evidence that the metabolite 
idarubicinol enters the CNS.13 Mitoxantrone was chosen 
as the test drug on the basis of its chemosensitivity proﬁ le 
in relapsed acute lymphoblastic leukaemia14 and a reported 
B-cell speciﬁ c eﬀ ect.15 Whereas idarubicin is a topoisom-
erase IIα poison and targets cycling cells, the additional 
inhibition of topoisomerase-IIβ activity by mitoxantrone 
was thought to have an advantage against more quiescent 
cells.16 The detection of minimal residual disease by real-
time PCR (RQ-PCR) analysis of antigen receptors17 at the 
end of induction was used to select patients for allogenic 
stem-cell transplant (allo-SCT) and to establish the 
kinetics of the randomised therapeutic response. In this 
Article, we report the outcome of this randomisation.
Methods
Patients
Patients aged 1–18 years with a ﬁ rst relapse of acute 
lymphoblastic leukaemia who had not received an 
allo-SCT in ﬁ rst complete remission were eligible. Those 
with mature B-acute lymphoblastic leukaemia were 
excluded. The study opened in January, 2003, in 
22 participating centres of the Children’s Cancer and 
Leukaemia Group (CCLG) in the UK and Ireland. In 
November, 2006, nine centres of the Australian 
and New Zealand Children’s Haematology/Oncology 
Group (ANZCHOG) joined the trial. This analysis is 
based on a snapshot of the data taken in June, 2009. 
Ethics approval in the UK was obtained from MREC for 
Wales and from institutional ethics committees outside 
the UK. Written informed consent was obtained from 
patients or from parents or legal guardians.
Randomisation and masking
Patients were randomly assigned to receive either 
mitoxantrone or idarubicin on days 1 and 2 of induction. 
The trial statistician generated randomisation lists by 
stratiﬁ ed block randomisation with varying block sizes, 
stratiﬁ ed by risk group and study group (CCLG or 
ANZCHOG).  ALLR3 was run on a custom built, web-
enabled database with decision support systems allowing 
data entry by participating centres or groups; centres 
could therefore enrol patients directly, with treatment 
being assigned by the computer according to centrally 
held lists, which enabled allocation concealment.
Procedures
A marrow relapse was deﬁ ned as more than 25% blasts 
in the bone marrow. CNS relapse was deﬁ ned as more 
than 5 white blood cells per μL with morphological 
evidence of blasts in the cerebrospinal ﬂ uid (CSF). 
Testicular disease was diagnosed clinically and 
conﬁ rmed with ultrasonography or by biopsy. The sites 
of relapse were deﬁ ned as isolated bone marrow, isolated 
extramedullary, or combined (>5% blasts in the bone 
marrow along with at least one extramedullary site). 
Time to relapse was classiﬁ ed as very early within 
18 months of ﬁ rst diagnosis, early after 18 months of 
ﬁ rst diagnosis but within 6 months after end of therapy, 
and late if more than 6 months after end of therapy.4 
The time to relapse, site of relapse, and immuno-
phenotype were used to risk stratify patients into 
standard-risk, intermediate-risk, and high-risk groups 
(ﬁ gure 1).
Patients were deﬁ ned as having achieved a second 
complete remission if they had less than 5% blasts in the 
marrow or no blasts in the CSF at the end of phase 1 (ﬁ rst 
timepoint, ﬁ gure 1). Minimal residual disease was 
measured from marrow samples obtained at diagnosis, 
at the end of induction (ﬁ rst timepoint), and after phase 3 
(second timepoint). At ﬁ rst timepoint, low minimal 
residual disease was deﬁ ned as fewer than 10–⁴ cells with 
two sensitive markers (quantitative range 10–⁴) and high 
minimal residual disease by at least one marker of 
10–⁴ cells or more. All others were classiﬁ ed as 
indeterminate. Minimal residual disease was not 
estimated in isolated extramedullary disease. All patients 
received three consecutive blocks of chemotherapy 
(ﬁ gure 1 and table 1) and patients in both groups were 
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Figure 1: Risk stratiﬁ cation (A) and trial design (B)
(A) Stratiﬁ cation according to immunophenotype, site of relapse, and time to relapse. Risk groups: very early refers 
to less than 18 months from ﬁ rst diagnosis; early refers to 18 months or more after ﬁ rst diagnosis and less than 
6 months from stopping therapy; and late refers to 6 months or more after stopping therapy. (B) MRD sampling 
TPs are marked. At TP1, standard-risk and intermediate-risk patients with MRD lower than 10–4 cells were ineligible, 
and high-risk and intermediate-risk patients with MRD of 10–4 cells or more were eligible for allo-SCT. Localised 
radiotherapy was given to those with extramedullary disease and not proceeding to allo-SCT. When MRD 
assessment was not possible in intermediate-risk patients, allo-SCT was allowed provided relapse occurred within 
24 months of stopping therapy. Details of the phases are provided in table 1. MRD=minimal residual disease. 
TP=timepoint. Allo-SCT=allogenic stem-cell transplant.
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allocated to allo-SCT according to risk groups and 
minimal residual disease (ﬁ gure 1).
Cytogenetic analysis was done locally and reviewed 
centrally by the Leukaemia Research Cytogenetics Group. 
When relapse cytogenetics was not done (eg, isolated 
extramedullary relapse), the original diagnostic 
cytogenetics was used. Outcome after ﬁ rst relapse was 
used to deﬁ ne the poor-risk cytogenetic group used in 
these analyses (see webappendix p 1).
For the randomised comparison, progression-free 
survival was the primary outcome. Progression-free 
survival was deﬁ ned as time from randomisation to the 
ﬁ rst of induction failure (5% blasts or more in bone 
marrow at ﬁ rst timepoint, persistence of CSF blasts, non-
regression of testicular enlargement), relapse, death from 
any cause, or a second malignancy. Secondary outcomes 
were overall survival, deﬁ ned as the time from 
randomisation to death from any cause, and proportion of 
patients in the intermediate-risk group with low minimal 
residual disease at ﬁ rst timepoint. Adverse events were 
graded according to the NCI Common Terminology 
Criteria for Adverse Events (CTCAE) v 3.0.18 Safety was 
summarised for all patients by the number of toxic eﬀ ects 
during the trial scored at CTCAE18 grade 3 or higher, 
and the proportion of patients having a serious 
adverse event.19
Statistical analysis 
The ﬁ rst planned interim analysis (May, 2007) drew 
attention to diﬀ erences in overall survival and 
progression-free survival between the two groups, and, 
after 6 months of further observation,  an independent 
data-monitoring committee recommended closure of the 
randomisation. Final analysis of randomised objectives 
did not take place until 2009 to allow the data to mature. 
No adjustment to results in this analysis was made to 
account for previous observations of the data.
We included all randomised patients from all study 
groups in the main analysis, analysed by intention-to-
treat apart from three ineligible patients excluded and 
one patient censored at the time of major protocol 
violation. Analysis was repeated in UK patients only as 
a secondary objective. For progression-free and overall 
survival the primary analysis was done by Kaplan-Meier 
plot and (unstratiﬁ ed) log-rank test. Multiple Cox 
regression was done to assess treatment eﬀ ect after 
adjustment for prespeciﬁ ed prognostic covariates: 
study group, risk group (treated as ordinal), 
ETV6-RUNX1, age group (1–<6, 6–10, and ≥10 years), 
and sex. We used multiple imputation to impute 
missing ETV6-RUNX1 data. The Cox model for 
progression-free survival was used to separately assess 
interactions of the randomly assigned drug with the 
following variables: immunophenotype, site, time 
from diagnosis to relapse (continuous), and minimal 
residual disease at the ﬁ rst timepoint (<1×10–⁴ or 
≥1×10–⁴ cells). For minimal residual disease, only 
Dose Days
Phase 1—induction (weeks 1–4) 
Intrathecal methotrexate*  .. 1, 8 
Dexamethasone oral 20 mg/m² 1–5; 15–19 
Mitoxantrone IV or idarubicin IV 10 mg/m² 1, 2 
Vincristine IV 1·5 mg/m² 3, 10, 17, 24 
PEG-asparaginase IM† 1000 u/m² 3, 18 
Phase 2—consolidation (weeks 5–8) 
Dexamethasone oral 6 mg/m² 1–5 
Vincristine IV 1·5 mg/m² 3 
Intrathecal methotrexate*  .. 8 
Methotrexate IV‡ 1000 mg/m² 8 
PEG-asparaginase IM† 1000 u/m2 9 
Cyclophosphamide IV 440 mg/m2 15–19 
Etoposide IV 100 mg/m² 15–19 
Phase 3—intensiﬁ cation (weeks 9–12) 
Intrathecal methotrexate*  .. 1, 22 
Dexamethasone oral 6 mg/m² 1–5 
Vincristine IV 1·5 mg/m² 3 
Cytarabine IV, every 12 h 3000 mg/m² 1, 2, 8, 9 
Erwinase IM 20000 u/m² 2, 4, 9, 11, 23 
Methotrexate IV‡  1000 mg/m² 22 
Phase 4—before SCT§ 
Fludarabine IV 25 mg/m² 1–5 
Cytarabine IV 2000 mg/m² 1–5 
Liposomal daunorubicin citrate IV 100 mg/m² 1 
Phase 5—before continuation (weeks 14–29)¶ 
Intrathecal methotrexate|| .. 1, 43, 57, 99 
Dexamethasone oral 6 mg/m² 1–5, 57–61 
6-mercaptopurine oral 75 mg/m² 1–42, 57–98 
Vincristine IV 1·5 mg/m² 3, 59 
Methotrexate oral 20 mg/m² 10,17, 31, 38, 67, 74, 88, 95 
Methotrexate every 6 h 25 mg/m² 22, 78 
Etoposide IV 150 mg/m² 42, 49, 99, 106 
Cyclophosphamide IV 300 mg/m² 42, 49, 99, 106 
Cytarabine IV 50 mg /m² 43–46, 50–53, 100–103, 
107–110 
Phase 6—continuation treatment (weeks 30—104)¶ 
Dexamethasone oral, every 4 weeks 6 mg/m² 1–5 
Vincristine IV, every 4 weeks 1·5 mg/m² 1 
Intrathecal methotrexate,* every 12 weeks .. .. 
6-mercaptopurine oral, daily 75 mg/m² .. 
Methotrexate oral, weekly 20 mg/m² .. 
IV=intravenous. PEG=polyethylene glycol. IM=intramuscular. SCT=stem-cell transplant. q6h=every 6 h. 
MRD=minimal residual disease. TP=timepoint. Dexamethasone was given as two divided doses with a maximum 
daily dose of 40 mg. Patients were randomly assigned to receive either idarubicin or mitoxantrone. *Doses of 
intrathecal methotrexate were age-related: 8 mg for children younger than 2 years, 10 mg for those aged 2 years, 
and 12 mg for children older than 2 years. †Six doses of erwinase, 20 000 u IM on alternate days, replaced each 
dose of PEG-asparaginase for those with a known allergy to E coli asparaginase. ‡Methotrexate was infused over 
36 h and calcium folinate rescue started 48 h from start of infusion. §Only patients with an MRD of 10–³ cells or 
higher at TP2 were eligible for phase 4. ¶Phases 5 and 6 were given to patients who were not transplanted. 
Patients with testicular or CNS disease received 24 Gy as fractionated treatment before start of phase 5. ||Oral 
methotrexate replaced intrathecal methotrexate for patients who had received cranial irradiation. Oral 
methotrexate was not given on the weeks of intrathecal methotrexate.
Table 1: Therapeutic protocol 
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intermediate-risk patients with bone marrow or 
combined relapse were included. Logistic regression, 
with and without the covariates, was used to explore 
the relation between the drugs and minimal residual 
disease at the ﬁ rst timepoint in intermediate-risk 
patients, for whom a measurement of minimal residual 
disease was available.
The number of toxic eﬀ ects at grade 3 or higher per 
patient was modelled with Poisson regression.20 We 
compared the number of patients who had at least one 
serious adverse event between treatments with a χ² test, 
and relative risk is presented. An exploratory compet ing 
risks analysis used the Fine and Gray model21 and 
Gray’s test,22 splitting events of progression-free sur-
vival into disease-related events (progression, relapse, 
disease-related deaths) and treatment-related events 
Figure 2: Trial proﬁ le
All patients were scheduled to receive two doses of anthracycline. Data for having received the drug were not 
available for 12 patients, six in each group.
239 patients registered
22 not randomised
5 physician’s choice
8 consent refused
4 randomisation service unavailable
5 reason not given
216 randomly assigned
105 allocated mitoxantrone111 allocated idarubicin
103 analysed109 analysed
109 compliance with 
randomised drug
101 received full dose
2 received partial dose
0 did not receive drug
6 no data 
103 compliance with 
randomised drug
96 received full dose
0 received partial dose
1 did not receive drug 
because died before 
treatment
6 no data 
2 excluded
1 site not open
1 database 
error—not real 
patient
2 excluded
2 ineligible—not
relapsed acute
lymphoblastic
leukaemia
1 excluded
1 not meeting inclusion criteria
Idarubicin Mitoxantrone
n 109 103
Sex
Boys 70 (64%) 61 (59%)
Girls 39 (36%) 42 (41%)
Age at ﬁ rst relapse (years)   
Median (IQR) 9·1 (6·4–13·1) 9·6 (7·0–12·9)
1–<6 22 (20·2%) 10 (9·7%)
6–9 42 (38·5%) 45 (43·7%)
≥10 45 (41·3%) 48 (46·6%)
Immunophenotype (B:T)   
B 95 (87·2%) 93 (90·3%)
T 14 (12·8%) 10 (9·7%)
Time to relapse (months)   
Median (IQR) 37·4 (24·0–55·1) 42·8 (29·6–57·5)
Very early 14 (12·8%) 12 (11·7%)
Early 40 (36·7%) 25 (24·3%)
Late 55 (50·5%) 66 (64·1%)
Site of relapse   
Isolated extramedullary 32 (29·4%) 20 (19·4%)
Isolated marrow 56 (51·4%) 67 (65·1%)
(Continues in next column)
Idarubicin Mitoxantrone
(Continued from previous column)
Combined 21 (19·3%) 16 (15·5%)
Risk group   
Standard 5 (4·6%) 3 (2·9%)
Intermediate 80 (73·4%) 76 (73·8%)
High 24 (22·0%) 24 (23·3%)
Age at ﬁ rst diagnosis   
Median (IQR) 5·0 (2·9–8·7) 5·3 (3·4–9·1)
<1 years 5 (4·6%) 1 (1·0%)
1–9 years 85 (78·0%) 83 (80·6%)
≥10 years 19 (17·4%) 19 (18·4%)
White-cell count at ﬁ rst diagnosis 
<50 × 109 cells per L 61 (56·0%) 69 (67·0%)
≥50 × 109 cells per L 22 (20·2%) 20 (19·4%)
Unknown 26 (23·9%) 14 (13·6%)
Cytogenetics  
High hyperdiploid 22 (20·2%) 32 (31·1%)
ETV6-RUNX1 17 (15·6%) 14 (13·6%)
Normal 8 (7·3%) 7 (6·8%)
Poor 12 (11·0%) 9 (8·7%)
Other 41 (37·6%) 30 (29·1%)
Unknown 9 (8·3%) 11 (10·7%)
High risk 24 24
Isolated extramedullary 1 (4·2%) 4 (16·7%)
Isolated marrow 20 (83·3%) 17 (70·8%)
Combined 3 (12·5%) 3 (12·5%)
T cell 7 (29·2%) 8 (33·3%)
Intermediate and standard risks 85 79
Isolated extramedullary 31 (36·5%) 16 (20·3%)
Isolated marrow 36 (42·4%) 50 (63·3%)
Combined 18 (21·2%) 13 (16·5%)
Data are number (%) unless otherwise indicated. IQR=interquartile range, 
numbers in brackets show lower and upper quartiles. MLL=patients with myeloid-
lymphoid or mixed lineage leukaemia rearrangements. Ph+=philadelphia-
chromosome positive. TCF3=includes patients with TCF3-PBX1 and TCF3-HLF 
fusions.
Table 2: Characteristics of randomised patients
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(treatment-related deaths, second malignancies). Web-
appendix pp 2–3 provides further details.
This study is registered, reference number 
ISCRTN45724312.
Role of the funding source 
The sponsors and funders of the study had no role in 
study design, data collection, data analysis, data 
interpretation, or writing of this report. The 
corresponding author had full access to all the data and 
had ﬁ nal responsibility for the decision to submit for 
publication.
Results
Of the 239 consecutive patients registered in the study, 
216 were randomly assigned to either idarubicin 
(n=111 patients) or mitoxantrone (n=105 patients), of 
whom 109 and 103 patients, respectively, were analysed 
(ﬁ gure 2). The two randomised groups were similar in 
sex, age at relapse, and immunophenotype (table 2). 
Although risk groups were balanced, we noted diﬀ erences 
between the treatment groups with regard to site, time to 
relapse, and cytogenetic subtypes. The mitoxantrone 
group had more late recurrences, isolated marrow 
relapses, and high hyperdiploid patients than did the 
idarubicin group (table 2).
The median follow-up was 41 months in both groups 
(95% CI 34–48 for idarubicin and 35–46 for mitoxantrone, 
reverse Kaplan-Meier method). Table 3 shows treatment 
outcomes to June, 2009. 108 (51%) of 212 evaluable 
patients are in second complete remission: 45 of 
109 (41%) in the idarubicin group and 63 of 103 (61%) in 
the mitoxantrone group. Of the 56 subsequent relapses, 
a third complete remission was achieved in six of 
38 patients in the idarubicin group and three of 
18 patients in the mitoxantrone group. 49 patients were 
transplanted in each group. 16 (33%) patients relapsed 
after allo-SCT in the idarubicin group and two (4%) in 
the mitoxantrone group.
The estimated 3-year progression-free survival of the 
whole group was 50·3% (95% CI 42·9–57·3) and overall 
survival 57·1% (49·5–63·9). Progression-free survival 
Idarubicin Mitoxantrone
SCT No SCT SCT No SCT 
End of phase 1 (TP1)
High risk 21 .. 14 ..
Intermediate and standard risk
High MRD 21 .. 24 ..
Low MRD .. 16 17
Extramedullary 24 5 12 2
Indeterminate 9 3 9 9
Total 75 24 59 28
End of phase 2
Withdrawn 1 .. .. ..
Relapse 2 .. .. ..
Treatment-related mortality 1 1 1 ..
End of phase 3 (TP2)
Relapse 7 .. 1 ..
Treatment-related mortality 5 .. .. ..
Total 59 23 57 28
Phase 4
Relapse 1 NA 1 NA 
Treatment received: not transplanted
Relapse 9 3 8 6
Second remission 1 18 4 17
Treatment-related mortality .. 1 .. ..
Treatment received: transplanted
Relapse 16 .. 2 ..
Treatment-related mortality 6 .. 2 2
Accident 1 .. 1 ..
Second remission 25 1 39 3
In phase 1, of the patients treated with mitoxantone, three withdrew, eight failed 
induction and there were ﬁ ve treatment-related mortalities. Of the patients who 
were treated with idarubicin, ﬁ ve failed induction and there were ﬁ ve treatment-
related mortalities. Patients were allocated at the end of phase 1 to either receive 
an allo-SCT (SCT) or continue in chemotherapy with or without radiotherapy 
(No SCT). Allo-SCT=allogenic stem-cell transplant. MRD=minimal residual disease. 
Table 3: Trial outcome as at June, 2009
Figure 3: Kaplan Meier estimates of progression-free (A) and overall (B) 
survival by randomised treatment
3-year estimated survival percentages (95% CI) are presented.
Number at risk
Mitoxantrone
Idarubicin
Number at risk
Mitoxantrone
Idarubicin
103
109
76
66
54
36
40
20
21
13
10
5
0
0·25
0·50
0·75
1·00
Pr
op
or
tio
n 
pr
og
re
ss
io
n-
fre
e
Log-rank p=0·0004
35·9 (25·9–45·9)
64·6 (54·2–73·2)
Mitoxantrone
Idarubicin
A
0
103
109
12
82
74
24
58
46
36
43
27
48
23
16
60
0 12 24 36 48 60
10
6
Months from randomisation
0
0·25
0·50
0·75
1·00
Pr
op
or
tio
n 
su
rv
iv
in
g
Log-rank p=0·004
45·2 (34·5–55·3)
69·0 (58·5–77·3)
B
Articles
2014 www.thelancet.com   Vol 376   December 11, 2010
and overall survival were signiﬁ cantly better for 
mitoxantrone than for idarubicin (ﬁ gure 3). Mitoxantrone 
almost halved the hazard of an event at any given 
timepoint for both progression-free and overall survival. 
The adjusted hazard ratio (HR) for progression-free 
survival was 0·54 (95% CI 0·36–0·82, p=0·003) and for 
overall survival was 0·56 (0·36–0·87, p=0·01) 
(webappendix p 4). The results remained unchanged 
when analysis was restricted to UK patients only 
(webappendix p 4). We next tested the eﬀ ect of potential 
imbalances due to prognostic factors in the two 
randomised groups (table 2). Neither covariate adjustment 
nor interactions signiﬁ  cantly altered the treatment eﬀ ect 
(ﬁ gure 4 and web appendix p 4). Sensitivity analysis 
conﬁ rmed the robustness of this ﬁ nding (webappendix 
p 5). The diﬀ erence between groups remained signiﬁ cant 
and of similar magnitude to the primary analysis.
For high-risk patients no clinical decision was made on 
the basis of minimal residual disease at timepoint 1. 
Hence, few data were available for these patients. In the 
high-risk group, of the seven patients with high minimal 
residual disease at ﬁ rst timepoint, ﬁ ve had more than 
10–³ cells at second time point, which suggests that 
postinduction chemotherapy did not reduce disease 
burden for these patients. No patients with a low minimal 
residual disease at the ﬁ rst timepoint had high minimal 
residual disease at the second timepoint in either high-
risk or intermediate-risk groups. We noted no apparent 
diﬀ erence between the two drugs in minimal residual 
disease at ﬁ rst timepoint in the intermediate-risk group 
(table 3 and webappendix p 6). Thus, the decreased 
relapse rate in the mitoxantrone group seemed to be 
unrelated to the kinetics of disease clearance (adjusted 
odds ratio for low minimal residual disease 1·06, 95% CI 
0·42–2·67, p=0·90).
During the whole trial, the number of toxic eﬀ ects at 
grade 3 or higher was signiﬁ cantly lower for patients given 
mitoxantrone than for those given idarubicin (inci-
dence rate ratio mitoxantrone:idarubicin 0·86, 95% CI 
0·75–0·98, p=0·02; webappendix p 7). Toxic eﬀ ects during 
phases 1 and 2 were signiﬁ cantly higher for patients given 
idarubicin and, compared with mitoxantrone, were mainly 
of an hepatic and gastrointestinal nature (webappendix 
pp 6–7). We recorded no signiﬁ cant randomised drug 
eﬀ ect during phases 3 and 4. Toxic eﬀ ects in phases 5 
and 6 were signiﬁ cantly worse for patients given 
mitoxantrone who, compared with those who received 
idarubicin, showed a delay in haemopoietic recovery, 
although the number of toxic eﬀ ects was low (webappendix 
pp 6–7). No signiﬁ cant randomised drug eﬀ ect was 
recorded after allo-SCT. Separation of progression-free 
survival into disease-related and treatment-related events 
showed that mitoxantrone reduced the risk of disease-
related events (HR 0·56, 95% CI 0·34–0·92; Gray’s test 
p=0·007), whereas the eﬀ ect on toxicity was not signiﬁ cant 
(HR 0·52, 0·24–1·11; Gray’s test p=0·11; table 4 and 
webappendix p 7).
Discussion
The results from this trial clearly show that, compared 
with idarubicin, mitoxantrone signiﬁ cantly improves the 
outcome of children with relapsed acute lymphoblastic 
Figure 4: Randomised drug eﬀ ect on progression-free survival by patient characteristics, from Cox models 
with interactions
p values for interaction test the hypothesis that the randomised treatment eﬀ ect varies between the diﬀ erent 
subgroups. Hazard ratios indicate that all subgroups show a treatment eﬀ ect favouring mitoxantrone. HR=hazard 
ratio. MRD=minimal residual disease. Cyto=cytogenetic subgroups. *Poor refers to poor outcome after relapse 
(webappendix p 2).
B cell
T cell
Isolated bone marrow
Combined
Isolated extramedullary
Intermediate-risk low MRD
Intermediate-risk high MRD
Relapse at 12 months
Relapse at 24 months
Relapse at 36 months
Age 1–<6 years
Age 6–<10 years
Age ≥10 years
High hyperdiploid
ETV6-RUNX1
Normal cyto
Poor cyto*
Other cyto
Unknown cyto
All patients
0·46 (0·30–0·73)
0·68 (0·23–1·96)
0·68 (0·38–1·19)
0·24 (0·08–0·68)
0·42 (0·19–0·94)
0·51 (0·12–2·13)
0·36 (0·11–1·22)
0·57 (0·30–1·08)
0·53 (0·33–0·83)
0·48 (0·32–0·73)
0·72 (0·26–2·02)
0·37 (0·18–0·78)
0·63 (0·36–1·11)
0·31 (0·12–0·79)
0·24 (0·05–1·20)
0·47 (0·11–2·03)
0·87 (0·33–2·30)
0·66 (0·34–1·25)
0·93 (0·19–4·51)
0·54 (0·36–0·82)
188
24
123
37
52
33
49
32
87
93
54
31
15
21
71
20
212
0·53
0·22
0·73
0·54
0·47
0·55
Favours mitoxantrone  Favours idarubicin 
1·00·1 0·2 0·5 2·0
Variable Patients HR (95% CI) p for
interaction
Idarubicin  Mitoxantrone
Treatment-related 19 (17·4%) 10 (9·7%)
Second malignancy 1 (0·9%) 0 (0·0%)
Treatment-related death 18 (16·5%) 10 (9·7%)
Disease-related 46 (42·2%) 27 (26·2%)
Refractory 5 (4·6%)  8 (7·8%)
Second relapse 38 (34·9%) 17 (16·5%)
Disease-related death 3 (2·8%) 2 (1·9%)
Other death 1 (0·9%) 1 (1·0%)
No events
Censored 43 (39·4%) 65 (63·1%)
Data are number (%) unless otherwise indicated. The number of disease-related 
deaths is low because most disease-related deaths occurred after a second relapse 
or after refractory disease, and hence do not constitute progression-free 
endpoints.  
Table 4: Endpoint of progression-free survival grouped by competing risks
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leukaemia. The trial ran across all 22 centres in the UK 
and Ireland and nine of ten centres in Australia and 
New Zealand. Although frontline protocols for both 
groups diﬀ er, the result of the randomisation was similar 
between the two study groups. Table 5 summarises the 
outcomes in studies in children with relapsed acute 
lymphoblastic leukaemia. Randomised trials in this 
disorder are infrequent, and this trial reports a valuable 
result. Unique to this study were the randomisation of 
anthracyclines in induction and the choice of 
mitoxantrone as test drug. Although mitoxantrone was 
less toxic than idarubicin, the eﬀ ect was mainly due to 
better disease control. For the UK, the 3-year overall 
survival of 69% achieved in the mitoxantrone group is a 
substantial improvement compared with the overall 
survival of 56% achieved in the preceding ALLR2 trial.4
The decision to stop the randomisation was based on 
the signiﬁ cant diﬀ erence in deaths between the two 
groups. Although we are aware of at least two other trials 
of childhood acute lymphoblastic leukaemia27,28 that 
reported early, they both recruited most of their target 
population. To our knowledge the closure of 
randomisation halfway through the trial, with this 
magnitude of diﬀ erence attributable to one drug, is 
unheralded in clinical trials in childhood acute 
lymphoblastic leukaemia. Continuation of follow-up 
vindicates the decision by the data-monitoring committee 
to close the randomisation (webappendix p 2). Early 
closure resulted in lower than calculated recruitment to 
the two groups of the study and the resulting 
disproportionate numbers within the subgroups. Never-
theless, within the limitations posed by the closure, we 
can be certain that mitoxantrone provided a signiﬁ cant 
survival advantage in our cohort of relapsed patients.
If the diﬀ erence between the two drugs was mainly that 
of chemosensitivity, we would have expected to detect a 
diﬀ erence in minimal residual disease at the ﬁ rst 
timepoint, which was not the case. To enable the quick 
assessment of the number of new drugs now in the 
pipeline, study designs are incorporating the use of 
minimal residual disease as a surrogate marker of outcome. 
If we had opted to use such a study design, mitoxantrone 
would have been discarded. Our experience is thus a caveat 
for trial designs that propose to use surrogate markers of 
therapeutic response, such as minimal residual disease, as 
a primary endpoint to assess treatment response in phase 2 
and 3 trials.29,30 Both idarubicin and mitoxantrone are tissue 
bound after infusion and can be detected months later. 
Thus in the context of the results of this trial, mitoxantrone 
seemed to have a delayed cytotoxic eﬀ ect. Mitoxantrone, 
unlike idarubicin, is an anthracenadione. Other than the 
diﬀ erential action on topoisomerase II isoforms and 
quiescent cells, it also has the ability to create DNA 
adducts,31 stimulate binding of nuclear factor κB,32 and 
potentiate immune-based cell kill by tagging leukaemic 
cells with calcireticulin.33
Although all these mechanisms could have contributed 
to the delayed cytotoxic eﬀ ect, there is another intriguing 
possibility. First, three of ﬁ ve patients given mitoxan-
trone who had high minimal residual disease at the ﬁ rst 
timepoint and who were not transplanted for various 
reasons had recurrence. Thus, in the group with high 
minimal residual disease, sustained remission probably 
needs both mitoxantrone and allo-SCT. Second, although 
Randomisation Result of randomisation Number of patients 
(randomised)
Treatment 
protocol
Anthracycline Outcome (95% CI) or SE
All patients 
BFM (1991)23 Methotrexate 1 g/m² vs 12 g/m² NS 130* ALL-REZ BFM 85 Daunorubicin 6-year EFS 31% (4)
CCLG (2000)3 None .. 256 ALL R1 Epirubicin 5-year EFS 46% (40–52)
CCLG (2005)4 None, retrospective .. 150 ALL R2 Epirubicin 5-year EFS 56% (47–64)
BFM (2005)24 Timing of cytarabine and 
methotrexate in early relapse
NS 183 (56) ALL-REZ BFM 87 Daunorubicin 15-year OS 37% (3)
15-year EFS 30% (3)
BFM (2010)5,10 Methotrexate 1 g/m2 vs 5 g/m2 NS 525 (269) ALL-REZ BFM 90 Daunorubicin 10-year OS 36% (2)
10-year EFS 32% (2)
CCLG (2010) Idarubicin vs mitoxantrone In favour of mitoxantrone 212 (212) ALL R3 Mitoxantrone 3-year OS 69% (59–77)
3-year PFS 65% (54–73)
Selected cohort
†AEIOP (2002)25 None, retrospective, and 
prospective
.. 99 Various Idarubicin 4-year OS 25% (5)
4-year EFS 21% (5)
‡CCG (2007)6 None .. 347 Various Not speciﬁ ed 3-year OS 56% (3)
3-year EFS 45% (3)
§CCG/TACL (2010)26 None, retrospective .. 225 Various Not speciﬁ ed 5-year DFS 45% (3)
Conﬁ dence Intervals (CI) are presented as percentages (%) and standard error as ±. NS=no signiﬁ cant diﬀ erence. BFM=Berlin Frankfurt Münster. CCLG=Children’s Cancer and Leukaemia Group, UK. 
AEIOP=Associazione Italiana Ematologia Oncologia Pediatrica. CCG=Children’s Cancer Group, USA. TACL=Therapeutic Advances in Childhood Leukemia Consortium, USA. EFS=event-free survival. OS=overall 
survival. DFS=disease-free survival. PFS=progression-free survival. *Number randomised not stated. †All isolated extramedullary disease and late pre-B relapses and those with less than 25% blasts in the marrow 
were excluded. ‡Only relapses in NCI standard risk patients were analysed. §Isolated extramedullary relapses were excluded. 
Table 5: Reported outcomes of trials in relapsed childhood acute lymphoblastic leukaemia
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idarubicin was more toxic than mitoxantrone, this 
toxic eﬀ ect was mainly seen during the ﬁ rst 8 weeks 
of treatment. 
For the few patients who were not transplanted and 
continued on chemotherapy, haematological toxic 
eﬀ ects increased during the later phases in the 
mitoxantrone group. Thus, mitoxantrone might in 
some way aﬀ ect the haemopoietic stem-cell niche, 
making it a less favourable environment for the 
leukaemic cell and more conducive to the allograft. 
Further analyses of the eﬀ ects of mitoxantrone on 
malignant and normal cells are needed. Such studies 
have the potential to identify novel mechanisms for the 
eradication of this disease.
A randomised trial of mitoxantrone was previously 
done in childhood acute myeloid leukaemia.34 Results 
showed an improved disease-free survival and lower 
relapse rates in the mitoxantrone group compared with 
the daunorubicin group; however, these reduced rates 
did not translate into overall survival.34 Mitoxantrone 
has only been infrequently used in therapeutic trials in 
childhood acute lymphoblastic leukaemia. A perception 
that optimisation has been reached with available drugs 
has shifted focus towards newer drugs and targeted 
therapy. These drugs will be prohibitively expensive for 
many patients. Mitoxantrone is a cheap and readily 
available drug and clearly needs further clinical 
assessment in childhood acute lymphoblastic 
leukaemia. Most frontline protocols are now moving 
towards risk-stratifying treatment based on minimal 
residual disease after induction. Patients with positive 
minimal residual disease usually receive anthracycline-
containing delayed intensiﬁ cation blocks. Logically, 
assessment of the potential beneﬁ t of mitoxan trone in 
childhood acute lymphoblastic leukaemia would be in a 
randomised use of mitoxantrone in the delayed 
intensiﬁ cation phase of frontline treatment for high-
risk patients. Our results suggest that, while we wait for 
targeted therapies to become a reality, conventional 
cytotoxics still have a role in treatment of acute 
lymphoblastic leukaemia.
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